Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Effects of Esketamine Pre-administration on Blood Lymphocyte Subsets and Inflammatory Factors in Early Postoperative Period:


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT05180318

Organisation Name: Wuhan Union Hospital, China

Overal Status: Not yet recruiting

Start Date: June 1, 2022

Last Update: April 27, 2022

Lead Sponsor: Wuhan Union Hospital, China

Brief Summary: Evidences have showing that esketamine has anti-inflammatory and therapeutic effects on depression and cardiac surgery. The investigators' preliminary results suggest that combined prophylactic and therapeutic use of esketamine could decrease the plasma levels of pro-inflammatory cytokines after LPS-induced endotoxemia. The investigators also found that combined prophylactic and therapeutic use of esketamine could attenuate systemic inflammation and inflammatory multi-organ injury in mice after CLP-induced lethal sepsis.

Surgical trauma could elicit a marked inflammatory response with increased expression of pro-inflammatory cytokines, as well as postoperative immunosuppression. However, it remains unclear whether combined prophylactic and therapeutic use of esketamine could improve postoperative immunosuppression and alleviates systemic inflammatory response.

This project aims to study whether combined prophylactic and therapeutic use of esketamine could improve the decreased number of lymphocyte subsets and increased plasma pro-inflammatory cytokines.

Conditions:
  • Surgical Injury


Total execution time in seconds: 0.31245994567871